Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tawanda Gumbo

Showing results (121-130 of 204) with videos related to

Pageof 21
Sort By:
Antimicrobial Agents and Chemotherapy|September 18, 2013
Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congenersSandirai Musuka, Shashikant Srivastava, Chandima Wasana Siyambalapitiyage Dona, et al.
Antimicrobial Agents and Chemotherapy|March 2, 2016
Susceptibility Testing of Antibiotics That Degrade Faster than the Doubling Time of Slow-Growing Mycobacteria: Ertapenem Sterilizing Effect versus Mycobacterium tuberculosisShashikant Srivastava, Sander P van Rijn, A Mireille A Wessels, et al.
Antimicrobial Agents and Chemotherapy|December 30, 2006
Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropeniaTawanda Gumbo, George L Drusano, Weiguo Liu, et al.
The Journal of Antimicrobial Chemotherapy|November 5, 2025
Preclinical evaluation of epetraborole in the hollow fibre system model of Mycobacterium abscessus lung diseaseSanjay Singh, Gunavanthi D Boorgula, Minh-Vu H Nguyen, et al.
Microbiology Spectrum|December 10, 2025
Eravacycline pharmacokinetics/pharmacodynamics in the hollow fiber system model of <i>Mycobacterium abscessus</i> lung diseaseSanjay Singh, Avneesh Shrivastava, Gunavanthi D Boorgula, et al.
Antimicrobial Agents and Chemotherapy|September 7, 2006
Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasisTawanda Gumbo, George L Drusano, Weiguo Liu, et al.
Antimicrobial Agents and Chemotherapy|April 18, 2007
Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populationsTawanda Gumbo, Arnold Louie, Weiguo Liu, et al.
The Journal of Antimicrobial Chemotherapy|May 14, 2014
The pyrazinamide susceptibility breakpoint above which combination therapy failsTawanda Gumbo, Emmanuel Chigutsa, Jotam Pasipanodya, et al.
The Journal of Infectious Diseases|December 28, 2006
Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growthTawanda Gumbo, Arnold Louie, Weiguo Liu, et al.
Antimicrobial Agents and Chemotherapy|August 29, 2007
Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampinTawanda Gumbo, Arnold Louie, Mark R Deziel, et al.
Pageof 21

Showing results (121-130 of 204) with videos related to

Sort By:
Pageof 21
Antimicrobial Agents and Chemotherapy|September 18, 2013
Thioridazine pharmacokinetic-pharmacodynamic parameters "Wobble" during treatment of tuberculosis: a theoretical basis for shorter-duration curative monotherapy with congenersSandirai Musuka, Shashikant Srivastava, Chandima Wasana Siyambalapitiyage Dona, et al.
Antimicrobial Agents and Chemotherapy|March 2, 2016
Susceptibility Testing of Antibiotics That Degrade Faster than the Doubling Time of Slow-Growing Mycobacteria: Ertapenem Sterilizing Effect versus Mycobacterium tuberculosisShashikant Srivastava, Sander P van Rijn, A Mireille A Wessels, et al.
Antimicrobial Agents and Chemotherapy|December 30, 2006
Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropeniaTawanda Gumbo, George L Drusano, Weiguo Liu, et al.
The Journal of Antimicrobial Chemotherapy|November 5, 2025
Preclinical evaluation of epetraborole in the hollow fibre system model of Mycobacterium abscessus lung diseaseSanjay Singh, Gunavanthi D Boorgula, Minh-Vu H Nguyen, et al.
Microbiology Spectrum|December 10, 2025
Eravacycline pharmacokinetics/pharmacodynamics in the hollow fiber system model of <i>Mycobacterium abscessus</i> lung diseaseSanjay Singh, Avneesh Shrivastava, Gunavanthi D Boorgula, et al.
Antimicrobial Agents and Chemotherapy|September 7, 2006
Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasisTawanda Gumbo, George L Drusano, Weiguo Liu, et al.
Antimicrobial Agents and Chemotherapy|April 18, 2007
Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populationsTawanda Gumbo, Arnold Louie, Weiguo Liu, et al.
The Journal of Antimicrobial Chemotherapy|May 14, 2014
The pyrazinamide susceptibility breakpoint above which combination therapy failsTawanda Gumbo, Emmanuel Chigutsa, Jotam Pasipanodya, et al.
The Journal of Infectious Diseases|December 28, 2006
Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growthTawanda Gumbo, Arnold Louie, Weiguo Liu, et al.
Antimicrobial Agents and Chemotherapy|August 29, 2007
Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampinTawanda Gumbo, Arnold Louie, Mark R Deziel, et al.
Pageof 21